ProQR to Present at the JMP Securities Life Science Conference

LEIDEN, the Netherlands, June 16, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe diseases such as cystic fibrosis and Leber's congenital amaurosis, today announced that Daniel de Boer, Chief Executive Officer, will give a company presentation at the JMP Securities Life Science Conference on Tuesday, June 23, 2015 at 4pm ET. The conference is being held at The St. Regis in New York, NY, USA.                                           

The live and archived webcast of the presentation will be accessible from the 'Investor Relations' section of ProQR's website (www.proqr.com) under 'Events and Presentations'. The archived webcast will be available for 30 days following the presentation date.

About ProQR

ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe diseases such as cystic fibrosis and Leber's congenital amaurosis. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind. Since 2012.

ProQR Therapeutics N.V.: Smital Shah Chief Financial Officer T: +1 415 231 6431 [email protected]

Media inquiries: Gretchen Schweitzer MacDougall Biomedical Communications Direct: +49 172 861 8540 Main: +49 89 2424 3494 [email protected]

You May Also Be Interested In

• Kelso Technologies Inc. Financial Results for the Quarter Ended June 30, 2026
• Agibank Recognized as One of the World’s Top Fintechs in 'The World’s Top Fintech Companies' 2026 List
• Lovense Launches Remote 8.0 With an Upgraded Ecosystem Experience